Qualitative Platelet Disorders Treatment Market Share

North American Market Forecast

North America industry is likely to dominate majority revenue share of 32% by 2037. The growth of the market can be attributed majorly to the growing pharmaceutical sector. For instance, the pharmaceutical industry in the region has experienced fast growth as a result of the creation of several new products and treatments for a variety of illnesses, including platelet abnormalities. In addition, several innovative medications and therapies are being explored to address platelet problems. Further, gene therapy strategies that try to address genetic abnormalities leading to platelet problems are also being investigated, which as a result are also anticipated to contribute to the market growth in this region. More than 20% of the world's pharmaceutical manufacturing and over 40% of the market are both based in the US.

Middle East & Africa Forecast

The Middle East & Africa qualitative platelet disorders treatment market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market can be attributed majorly to the increasing frequency of qualitative platelet disorders. For instance, QPD is a genetic disease, which is why, it is more common in communities that practice intermarriage. Qualitative platelet disorders are often caused by genetic mutations, and some of these mutations may be more common in certain populations. For instance, the prevalence of Glanzmann thrombasthenia, a rare inherited platelet disorder, is found to be higher in populations with consanguineous marriages, which are more common in some parts of the Middle East & Africa, as a result, anticipated to boost the market growth during the forecast period